[ad_1]
With the acquisition of the pharmaceutical company Celgene, Bristol Myers Squibbs strengthens its offering of pharmaceutical and healthcare solutions. The company will also continue to collaborate with other healthcare providers to develop treatments for seriously ill patients.
In November last year, BMS, Bristol Myers Squibb, completed its acquisition of Celgene and the products of the two companies are now under the BMS brand.
– Both companies were successful both globally and here in Sweden. Together, we now have the opportunity to help more patients in various areas of disease. We already have several leading products on the market and in the next two years alone we will launch another eight new drugs, says Michaël Lugez, CEO of BMS Sweden and former CEO of Celgene Nordics.
Leading Biopharmaceutical Company
Prior to the merger, Celgene was a leading global player in the development of drugs for the treatment of, among other things, blood cancer diseases, solid cancer tumors, and inflammatory and immune diseases. BMS was a global biopharmaceutical company developing innovative drugs in oncology, cardiovascular disease, immunology, and fibrosis.
– Together we have one of the broadest pipelines in the industry and thanks to the fact that we can now combine the knowledge and experience of the two companies, we will be even stronger. Employees are our greatest asset and are driven by the search for new drugs and innovative treatment solutions for healthcare. Both Celgene and BMS have previously invested heavily in research globally as well and this is something we will continue with, says Michaël Lugez.
EXTERNAL LINK: Read more: this is how Bristol Myers Squibb works in Sweden.
In the coming years, BMS in Sweden intends to work towards three main goals.
– Our first priority now is to complete the merger of the companies so that patients can enjoy the benefits. Furthermore, our goal is to make our new products available to patients in Sweden as soon as possible. The third goal is to give our people more opportunities to grow and develop our business, says Michaël Lugez.
All patients are focused
Patients and their care are constantly focused on everything BMS does and the company wants to be involved throughout the patient journey. That is why they are now developing an app where patients can follow their treatment, get their questions answered, and speak with a doctor.
– We not only want to be a pharmaceutical supplier, but also a partner for everyone involved in health. BMS, for example, co-founded the organization “All.Can” whose goal is to free up resources for hospitals to optimize patient treatment. To achieve this, we must work together. Another example is how in the ongoing pandemic we work with other companies and organizations to donate money, laboratory equipment and products to support the fight against the coronavirus, says Michaël Lugez.
New logo
In connection with the Celgene acquisition, BMS also updates its brand with a new logo.
– Although we still call ourselves BMS, we are a new company and we want to show it with our new logo. The motif is a hand that is a universal symbol of healing. It represents giving and receiving care and shows our commitment to putting people first, it is personal, concludes Michaël Lugez.
EXTERNAL LINK: Read more about Bristol Myers Squibb here
Fakta Bristol Myers Squibb
Bristol Myers Squibb, BMS, is a global biopharmaceutical company developing innovative drugs for serious diseases. The company combines the flexibility of a biotech company with the reach and resources of an established pharmaceutical company. BMS is active in oncology, cardiovascular diseases, cancers, and inflammatory and immunological diseases. BMS participates in several global collaborations to develop and optimize patient-focused care solutions.
